Agios Pharmaceuticals AGIO Stock-Based Comp
Stock-Based Comp at other companies
Other financials
Where this comes from
Reported directly by Agios Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:ShareBasedCompensation.
The official record: Agios Pharmaceuticals’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →
Ask your AI about Agios Pharmaceuticals's stock-based comp.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Agios Pharmaceuticals's stock-based comp?
- Agios Pharmaceuticals (AGIO) reported stock-based comp of $15.54M in Q1 2026.
- How has Agios Pharmaceuticals's stock-based comp changed year-over-year?
- Agios Pharmaceuticals's stock-based comp increased by 36.8% year-over-year, from $11.36M to $15.54M.
- What is the long-term trend for Agios Pharmaceuticals's stock-based comp?
- Over 4 years (2021 to 2025), Agios Pharmaceuticals's stock-based comp has grown at a -0.4% compound annual growth rate (CAGR), from $53.51M to $52.55M.
- What does stock-based comp mean?
- Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.